Method for screening control drugs of drugs with same name and same prescription

Abstract

The invention belongs to the technical field of internet big data, and particularly relates to a method for screening same-name and same-party drug control drugs, which comprises the following steps: S1, acquiring basic information of listed drugs, performing data processing and standardization processing, and storing the basic information into a database A; s2, acquiring and processing admission-related data of drugs, and storing the data into a database B; s3, taking medicine names as keywords, and respectively matching basic data and access related data of each medicine from the database A and the database B; establishing a medicine entry of each medicine in the database C, and integrating the matched basic information of the medicine and the admission related data into the corresponding medicine entry; s4, according to research and development requirements of the same-name and same-prescription medicines, establishing screening conditions of the same-name and same-prescription control medicines; screening the data in the database C according to the screening conditions to obtain the same-name and same-prescription control drug data meeting the use requirements; the method can be used for rapidly and accurately screening out the same-name and same-prescription control drugs meeting various conditions.

Description

Technical Field

[0001] The present invention belongs to the technical field of Internet big data, and in particular relates to a method for screening control drugs for drugs with the same name and formula. Background Art

[0002] As an important category in the field of traditional Chinese medicine, drugs with the same name and prescription are those whose common names, prescriptions, dosage forms, functions and indications, usage and daily dosage are the same as those of the marketed traditional Chinese medicines with the same name and prescription, and whose effectiveness, safety and quality controllability are not inferior to those of the marketed traditional Chinese medicines. The research and development and promotion of such drugs not only help to ensure the safety and efficacy of patients' medication, but also promote the standardized development of the traditional Chinese medicine industry.

[0003] In order to ensure the quality, safety and effectiveness of drugs with the same name and formula, the Drug Evaluation Center of the State Drug Administration issued the "Technical Guidelines for the Study of Drugs with the Same Name and Formula (Trial)", which detailed the specific requirements for the selection of control drugs, the formulation of quality standards, and stability studies. With the release of the "Classification and Application Materials Requirements for Chinese Medicine Registration" and the "Technical Guidelines for the Study of Drugs with the Same Name and Formula (Trial)", Chinese medicine research and development companies have clearer classifications and guidance in the research and development and application process of drugs with the same name and formula, which provides companies with more development opportunities and also brings new challenges. The release of these policies may stimulate a wave of research and development and investment in drugs with the same name and formula, thereby breaking the original market structure of Chinese medicine products and promoting innovation and competition in the field of Chinese medicine research and development.

[0004] However, in actual operation, companies are faced with the problem of how to quickly and accurately select reference drugs with the same name and formula that meet various conditions. Due to the wide variety of Chinese medicines on the market, and the extremely complex basic information and access-related data of each drug, companies often need to screen and compare massive amounts of data, which undoubtedly increases the workload and time cost of the company. In addition, subtle differences between different drugs may also lead to deviations in the screening results, thereby affecting the research and development and application quality of drugs with the same name and formula.

[0005] The main reasons for this problem are: on the one hand, the diversity and complexity of drug information makes the screening process cumbersome; on the other hand, the lack of efficient and accurate screening methods and tools makes it difficult for companies to make quick judgments when faced with large amounts of data.

[0006] Therefore, how to quickly and accurately screen out control drugs with the same name and formula that meet all the conditions has become a problem that needs to be solved urgently. Summary of the invention

[0007] In view of the above-mentioned deficiencies in the prior art, the present invention provides a method for screening control drugs of the same name and formula, which can quickly and accurately screen out control drugs of the same name and formula that meet various conditions.

[0008] In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0009] A method for screening a control drug of a drug with the same name and formula, comprising the following steps:

[0010] S1. Obtain basic information of marketed drugs, perform data processing and standardization, and store the processed basic information of drugs in database A;

[0011] S2. Obtain and process drug access related data; store the processed drug access related data in database B;

[0012] S3. Using the drug name as a keyword, match the basic data and access-related data of each drug from database A and database B respectively; establish a drug entry for each drug in database C, and integrate the matched basic information and access-related data of the drug under the corresponding drug entry;

[0013] S4. According to the research and development requirements of drugs with the same name and formula, establish screening conditions for control drugs with the same name and formula; and screen the data in database C according to the screening conditions to obtain data of control drugs with the same name and formula that meet the use requirements;

[0014] Among them, S1 and S2 can be swapped in order.

[0015] Glossary: ​​Access-related data refers to data related to the standards, conditions or requirements that a drug must meet to enter the market or a specific sales channel. These data are usually developed and maintained by government regulatory agencies, industry associations or third-party organizations to ensure the safety, effectiveness and compliance of Chinese patent medicines.

[0016] Compared with the prior art, the present invention has the following beneficial effects:

[0017] 1. Using this method, through step S1, this method first obtains the basic information of marketed drugs, and performs data processing and normalization. This step ensures the accuracy and consistency of the data, laying a solid foundation for subsequent data matching and screening. At the same time, the processed data is stored in database A for subsequent data management and query. Step S2 obtains and processes the drug access-related data. These data are of great significance for evaluating the market access status and policy preferences of drugs. The processed access data is stored in database B, which complements the basic information to form a complete drug information system.

[0018] 2. In step S3, the method uses the drug name as a keyword to match the corresponding basic data and access data from database A and database B respectively. This step achieves rapid matching and integration of data, integrating relevant information under the corresponding drug entry in database C. This not only improves the utilization rate of data, but also facilitates subsequent data analysis and screening. It not only facilitates data access and management, but also provides convenience for subsequent screening work, ensuring the integrity and consistency of the data.

[0019] 3. Step S4 established screening conditions based on the R&D requirements of drugs with the same name and formula, and screened the data in database C based on these screening conditions. The flexibility of this step is that the screening conditions can be adjusted according to different R&D requirements, so as to obtain the data of control drugs with the same name and formula that meet specific conditions. Since the data has been integrated and standardized in the early stage, the accuracy of the screening results is guaranteed.

[0020] In summary, this method can quickly and accurately screen out control drugs with the same name and formula that meet all the conditions. Through data integration, matching and integration, flexible screening and other steps, this method not only improves the screening efficiency, but also ensures the accuracy and reliability of the screening results. This is of great significance to Chinese medicine research and development companies in the research and development and application process of drugs with the same name and formula, and helps promote the innovation and development of the Chinese medicine industry.

[0021] Preferably, in S1, the normalization process includes ATC classification.

[0022] With this setup, the basic information of marketed drugs can be organized according to a unified classification system through ATC classification to achieve data standardization. This helps eliminate differences between different data sources and improves data comparability and consistency. In addition, ATC classification provides a clear classification framework for drug information, allowing researchers to quickly locate drug information of interest. This greatly improves the efficiency of information retrieval and shortens the R&D cycle.

[0023] Preferably, in S1, data processing includes data matching and supplementation and data governance.

[0024] Such settings, data matching supplementation and data governance have significant effects. They jointly improve the accuracy, completeness and value of the data, and provide more comprehensive and accurate data support for subsequent drug research and development, production and other links.

[0025] Preferably, the data matching supplement includes: using the approval number as a unique value and data matching primary key information; querying relevant prescription information by matching the corresponding instruction manual standard source, and supplementing the prescription content to the marketed drug data set.

[0026] Such a setting, using the approval number as the primary key for matching, can greatly simplify the data matching process, reduce matching errors and manual intervention, and improve the efficiency of data processing. The approval number, as a unique identifier, helps to integrate data from different sources into a unified data set, facilitating subsequent data management and analysis. By matching the standard source of the instructions, detailed prescription information for each drug can be queried and added to the data set, making the data set more complete and rich.

[0027] Preferably, the content of data governance includes: removing dosage forms from the names of marketed drugs, aggregating drugs with the same name to obtain a data set of marketed drug varieties, which is used to standardize drugs with different names but the same prescriptions and count the number of manufacturers of the same variety.

[0028] With this setting, the drug names after removing the dosage form are more concise and clear, which helps to reduce the confusion of drug names caused by different dosage forms. The drug names after removing the dosage form are more unified, which facilitates subsequent data aggregation and analysis, and improves the efficiency and accuracy of data processing.

[0029] By aggregating drugs with the same name, we can obtain a data set of Chinese patent medicines listed on the market, which is helpful to integrate drug resources and improve the efficiency and level of drug management. The data set of Chinese patent medicines listed on the market provides important data support for drug supervision and decision-making, helps to strengthen the supervision and regulation of the drug market, and ensure the safety and effectiveness of public drug use.

[0030] Standardizing drugs with different names but the same prescription can avoid drug confusion and misuse caused by name differences. Counting the number of manufacturers of the same drug helps understand market competition and provides important reference for drug procurement, pricing and sales.

[0031] Preferably, the basic information of the drug includes the drug name, English name of the drug, approval number, specifications, number of manufacturers of the same variety and number of manufacturers of the same variety and specifications, latest and earliest approval dates, ATC classification, dosage form, manufacturer and address, prescription, prescription source, main functions, and registration category.

[0032] With this setup, 1. The basic information of the drug includes multiple aspects, from the drug name to the registration category, which together constitute a complete description of the drug. This comprehensiveness ensures the integrity of the data and provides a rich information foundation for subsequent data matching, integration and analysis.

[0033] 2. When screening for control drugs with the same name and prescription, these detailed basic information can be used as screening conditions to improve the accuracy of screening. For example, you can accurately match drugs that meet your needs based on specific information such as approval number, specifications, dosage form, and manufacturer, reducing the possibility of mismatching.

[0034] 3. It can also promote drug R&D decision-making. Complete basic drug information provides strong support for drug R&D decision-making. Researchers can use this information to evaluate the market potential, competition landscape and R&D risks of drugs, and provide a scientific basis for new drug R&D, drug improvement and drug registration.

[0035] In summary, the basic information of drugs covers multiple key aspects, providing strong support for data matching, integration, analysis and screening, which helps promote drug research and development innovation, improve drug supervision efficiency, enhance drug information transparency, and meet diverse analysis needs.

[0036] Preferably, the drug access-related data include protected varieties of traditional Chinese medicine, data on Chinese patent medicines in the pharmacopoeia, data on the medical insurance catalog, data on the basic drug catalog, and data on children's medicines.

[0037] Such a setting, 1. The protected Chinese medicine variety data provides strong support for the healthy development of the Chinese medicine industry. These data cover Chinese medicine varieties with significant efficacy verified by long-term clinical practice or rigorous modern medical research, which helps to encourage companies to increase R&D investment and improve the quality and safety of Chinese medicine. The protected Chinese medicine variety data ensures that patients can obtain high-quality Chinese medicine that has been strictly screened and approved, providing more reliable options for the treatment of diseases, thereby protecting the health rights and interests of the public.

[0038] 2. Pharmacopoeia Chinese patent medicine data provides an important basis for the standardized use of Chinese patent medicines. These data record the prescription, dosage, usage and other information of Chinese patent medicines in detail, which helps to ensure the safety and effectiveness of Chinese patent medicines in clinical use. Chinese patent medicine data can also provide data support for new drug research and development, helping researchers to understand the advantages and disadvantages of existing Chinese patent medicines, so as to make targeted improvements and optimizations in new drug research and development.

[0039] 3. The medical insurance catalogue data covers the drugs within the scope of medical insurance payment. The prices of these drugs are regulated by medical insurance policies, which helps to reduce the economic burden on patients. The medical insurance catalogue data can also provide a reference for the optimal allocation of medical resources. By analyzing the use of drugs in the medical insurance catalogue, we can understand the treatment needs and drug usage trends of different diseases, so as to rationally allocate medical resources.

[0040] 4. The data of the basic drug list covers drugs that meet basic medical needs. These drugs are relatively reasonably priced and of reliable quality, which helps to ensure the basic medical needs of the people. The data of the basic drug list can also provide support for improving the efficiency of medical services. By giving priority to the use of drugs in the basic drug list, unnecessary medication and examinations can be reduced, and the efficiency and quality of medical services can be improved.

[0041] 5. The children's medication data records in detail the information of drugs suitable for children, including dosage, usage, adverse reactions, etc., which helps to ensure the safety and effectiveness of children's medication. Children's medication data can also provide data support for the research and development of children's drugs. By analyzing the demand and trends of children's medication, we can understand the research and development direction and focus of children's drugs, thereby promoting the innovation and development of children's drugs.

[0042] In summary, drug access-related data have significant effects in many aspects, which have jointly promoted the healthy development of the pharmaceutical industry, protected the health rights and interests of the public, and improved the efficiency and quality of medical services. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to make the purpose, technical solution and advantages of the invention more clear, the present invention will be further described in detail below with reference to the accompanying drawings, in which:

[0044] Figure 1 Flowchart of this method. DETAILED DESCRIPTION

[0045] The following is a further detailed description through specific implementation methods:

[0046] Embodiment 1

[0047] like Figure 1 As shown, this embodiment discloses a method for screening a control drug of the same name and formula, comprising the following steps:

[0048] S1. Obtain the basic information of marketed drugs, perform data processing and standardization, and store the processed basic information of drugs in database A.

[0049] During specific implementation, the basic information of the drug includes the drug name, English name of the drug, approval number, specifications, number of manufacturers of the same variety and number of manufacturers of the same variety and specifications, the latest and earliest approval dates, ATC classification, dosage form, manufacturer and address, prescription, prescription source, main functions and indications, and registration category.

[0050] The basic information of drugs includes multiple aspects from drug names to registration categories, which together constitute a complete description of the drug. This comprehensiveness ensures the integrity of the data and provides a rich information basis for subsequent data matching, integration and analysis. In this way, when screening for control drugs with the same name and prescription, these detailed basic information can be used as screening conditions to improve the accuracy of screening. For example, according to specific information such as approval number, specification, dosage form, manufacturer, etc., drugs that meet the needs can be accurately matched to reduce the possibility of mismatching. In addition, it can also promote drug research and development decisions. Complete basic information on drugs provides strong support for drug research and development decisions. Based on this information, researchers can evaluate the market potential, competitive landscape and R&D risks of drugs, and provide a scientific basis for new drug research and development, drug improvement and drug registration. The basic information of drugs covers multiple key aspects, providing strong support for data matching, integration, analysis and screening, which helps to promote drug research and development innovation, improve drug supervision efficiency, enhance drug information transparency, and meet diverse analysis needs.

[0051] Among them, data processing includes data matching and supplementation and data governance. Data matching and supplementation and data governance have significant effects. They jointly improve the accuracy, completeness and value of data, and provide more comprehensive and accurate data support for subsequent drug research and development, production and other links.

[0052] In specific implementation, the content of data matching and supplementation includes: using the approval number as the unique value and data matching primary key information; querying the relevant prescription information by matching the corresponding standard source of the instructions, and supplementing the prescription content to the marketed drug data set. In this way, using the approval number as the primary key for matching can greatly simplify the data matching process, reduce matching errors and manual intervention, and improve the efficiency of data processing. As a unique identifier, the approval number helps to integrate data from different sources into a unified data set, which is convenient for subsequent data management and analysis. By matching the standard source of the instructions, the detailed prescription information of each drug can be queried and supplemented to the data set, making the data set more complete and rich.

[0053] The content of data governance includes: removing dosage forms from the names of marketed drugs, aggregating drugs with the same name to obtain a data set of marketed drug varieties, which is used to standardize drugs with different names but the same prescriptions and count the number of manufacturers of the same variety. In this way, the names of drugs after removing dosage forms are more concise and clear, which helps to reduce the confusion of drug names caused by different dosage forms. The names of drugs after removing dosage forms are more unified, which is convenient for subsequent data aggregation and analysis, and improves the efficiency and accuracy of data processing. By aggregating drugs with the same name, a data set of Chinese patent medicine varieties listed in China can be obtained, which helps to integrate drug resources and improve the efficiency and level of drug management. The data set of Chinese patent medicine varieties listed in China provides important data support for drug supervision and decision-making, helps to strengthen the supervision and regulation of the drug market, and ensures the safety and effectiveness of public drug use. Standardizing drugs with different names but the same prescriptions can avoid drug confusion and misuse caused by name differences. Counting the number of manufacturers of the same drug variety helps to understand the market competition and provide an important reference for drug procurement, pricing and sales.

[0054] In specific implementation, the standardized processing includes ATC classification. Through ATC classification, the basic information of marketed drugs can be sorted according to a unified classification system to achieve data standardization. This helps to eliminate the differences between different data sources and improve the comparability and consistency of data. In addition, ATC classification provides a clear classification framework for drug information, allowing researchers to quickly locate drug information of interest. This greatly improves the efficiency of information retrieval and shortens the R&D cycle.

[0055] S2. Obtain and process drug access-related data; store the processed drug access-related data in database B.

[0056] Access-related data refers to data related to the standards, conditions or requirements that a drug must meet to enter the market or a specific sales channel. These data are usually developed and maintained by government regulatory agencies, industry associations or third-party organizations to ensure the safety, effectiveness and compliance of Chinese patent medicines. In specific implementation, drug access-related data include protected Chinese medicine varieties, Chinese patent medicine data in the pharmacopoeia, medical insurance catalog data, basic drug catalog data, and children's drug data.

[0057] The data on protected Chinese medicine varieties provide strong support for the healthy development of the Chinese medicine industry. These data cover Chinese medicine varieties with significant efficacy that have been verified by long-term clinical practice or rigorous modern medical research, which will help encourage companies to increase investment in research and development and improve the quality and safety of Chinese medicine. The data on protected Chinese medicine varieties ensure that patients can obtain high-quality Chinese medicines that have been strictly screened and approved, providing more reliable options for the treatment of diseases, thereby protecting the health rights and interests of the public.

[0058] The data of Chinese patent medicines in the pharmacopoeia provide an important basis for the standardized use of Chinese patent medicines. These data record the prescriptions, dosages, usage and other information of Chinese patent medicines in detail, which helps to ensure the safety and effectiveness of Chinese patent medicines in clinical use. Chinese patent medicine data can also provide data support for new drug research and development, helping researchers to understand the advantages and disadvantages of existing Chinese patent medicines, so as to make targeted improvements and optimizations in new drug research and development.

[0059] The medical insurance catalogue data covers the drugs within the scope of medical insurance payment. The prices of these drugs are regulated by medical insurance policies, which helps to reduce the economic burden on patients. The medical insurance catalogue data can also provide a reference for the optimal allocation of medical resources. By analyzing the use of drugs in the medical insurance catalogue, we can understand the treatment needs and drug usage trends of different diseases, so as to rationally allocate medical resources.

[0060] The data of the basic drug list covers drugs that meet basic medical needs. These drugs are relatively reasonably priced and of reliable quality, which helps to ensure the basic medical needs of the people. The data of the basic drug list can also provide support for improving the efficiency of medical services. By giving priority to the use of drugs in the basic drug list, unnecessary medication and examinations can be reduced, and the efficiency and quality of medical services can be improved.

[0061] Children's medication data records in detail the information of drugs suitable for children, including dosage, usage, adverse reactions, etc., which helps to ensure the safety and effectiveness of children's medication. Children's medication data can also provide data support for the research and development of children's medicines. By analyzing the demand and trends of children's medication, we can understand the research and development direction and focus of children's medicines, thereby promoting the innovation and development of children's medicines.

[0062] In summary, drug access-related data have significant effects in many aspects, which have jointly promoted the healthy development of the pharmaceutical industry, protected the health rights and interests of the public, and improved the efficiency and quality of medical services.

[0063] S3. Using the drug name as a keyword, match the basic data and access-related data of each drug from database A and database B respectively; establish a drug entry for each drug in database C, and integrate the matched basic information and access-related data of the drug under the corresponding drug entry;

[0064] S4. According to the research and development requirements of drugs with the same name and formula, screening conditions for control drugs with the same name and formula are established; and the data in database C are screened according to the screening conditions to obtain data of control drugs with the same name and formula that meet the usage requirements.

[0065] Among them, S1 and S2 can be swapped in order.

[0066] During the specific implementation, two specific screening processes are used to illustrate the relevant contents.

[0067] Example 1

[0068] This example is about the construction of screening conditions for a control drug with the same name and formula. The reference standard for screening a control drug with the same name and formula is established. The standard is as follows:

[0069] 1. With reference to the national "Technical Guidelines for the Study of Drugs with the Same Name and Formula (Trial)", the safe and effective variety types of the control drugs are set as follows: (1) Traditional Chinese medicine protected varieties, the matching condition is that if the drug name in database A = the drug name of the traditional Chinese medicine protected variety in database B, then it is judged as yes; (2) Current pharmacopoeia varieties, the matching condition is that if the drug name in database A = the drug name of the traditional Chinese medicine in the pharmacopoeia in database B, then it is judged as yes; (3) Drugs approved in accordance with the drug registration management requirements, the judgment condition is that the drug registration type in database A data = "1.1or 1.2or 2or 3or 3.1or 4or 5or 6or 6.1or 6.2" and "approved for production after 2000", then it is judged as yes.

[0070] 2. With reference to relevant industry news and regulations, the types of drugs that are not recommended for generic control drugs are set as follows: (1) Health care drugs. The judgment condition is that the approval number of the data in database A contains "National Medicine Standard B", then the judgment is yes; (2) Drugs within the validity period of the Chinese medicine protection. The judgment condition is that the drug name in database A = the drug name of the protected Chinese medicine in database B and the protection expiration date has not expired, then the judgment is yes; (3) Chinese and Western medicine compound preparations. The judgment condition is that the prescription in the data in database A contains chemical drugs, then the judgment is yes; (4) Injection. The judgment condition is that the dosage form in the data in database A contains injection, then the judgment is yes.

[0071] 3. Whether it contains toxic medicinal materials, judgment condition: if the prescription medicinal materials in the database A data contain toxic medicinal materials, then it is judged as yes.

[0072] 4. Whether the prescription is public or not, judging condition: if the prescription in database A contains "etc." or does not contain the dosage of medicinal materials, it is judged as not public.

[0073] 5. Number of manufacturers of the same product: calculated by aggregating drugs with the same name;

[0074] 6. Number of prescription flavors: Count the number of prescription medicinal materials in database A;

[0075] 7. Dosage form, which is the dosage form of the drug in the data of database A;

[0076] 8. Medical insurance category: If the drug name in database A is equal to the drug name in the medical insurance catalog in database B, then it is judged as yes;

[0077] 9. Basic drugs: If the drug name in database A is equal to the drug name in the basic drug catalog of database B, then it is judged as yes;

[0078] 10. Product sales: Divide the ranges by the market sales data in database A.

[0079] Example 2

[0080] This example is a specific screening process of a pharmaceutical company's reference drug with the same name and formula according to the established screening conditions. A pharmaceutical company wants to develop a Chinese patent medicine with the same name and formula for cardiovascular and cerebrovascular diseases. Requirements: safe and effective, easy to apply, large market share, and low competitiveness. The screening process is as follows:

[0081] 1. Under ATC classification, select: Category C - Cardiovascular and cerebrovascular system;

[0082] 2. Positively select safe and effective reference drugs, and negatively eliminate reference drugs that are not recommended for copying. At this time, the number of remaining drugs is 172;

[0083] 3. Select non-toxic, and the number of remaining medicines is 148;

[0084] 4. Select Public Prescription Drugs, and the number of remaining drugs is 81;

[0085] 5. The number of manufacturers of the same product is selected to be within 3, and the number of remaining drugs is 55;

[0086] 6. The number of prescription ingredients is selected to be within 5, and the number of remaining medicines is 31;

[0087] 7. Select the products in the medical insurance catalog and basic drug catalog. At this time, the number of remaining drugs is 3. As shown in the following table.

[0088]

[0089] Using this method, through step S1, this method first obtains the basic information of marketed drugs, and performs data processing and normalization. This step ensures the accuracy and consistency of the data, laying a solid foundation for subsequent data matching and screening. At the same time, the processed data is stored in database A for subsequent data management and query. Step S2 obtains and processes the access-related data of the drug. These data are of great significance for evaluating the market access and policy preferences of drugs. The processed access data is stored in database B, which complements the basic information to form a complete drug information system. In step S3, this method uses the drug name as a keyword to match the corresponding basic data and access data from database A and database B respectively. This step realizes the rapid matching and integration of data, and integrates the relevant information under the corresponding drug entry in database C. Doing so not only improves the utilization rate of the data, but also facilitates subsequent data analysis and screening. It not only facilitates the access and management of data, but also provides convenience for subsequent screening work, ensuring the integrity and consistency of the data. Step S4 establishes screening conditions based on the research and development needs of drugs with the same name and prescription, and screens the data in database C based on these screening conditions. The flexibility of this step is that the screening conditions can be adjusted according to different R&D needs, so as to obtain the data of the same-name and same-formula control drugs that meet specific conditions. Since the data has been integrated and standardized in the early stage, the accuracy of the screening results is guaranteed. In summary, this method can quickly and accurately screen out the same-name and same-formula control drugs that meet various conditions. Through data integration, matching and integration, flexible screening and other steps, this method not only improves the screening efficiency, but also ensures the accuracy and reliability of the screening results. This is of great significance to Chinese medicine R&D companies in the R&D and application process of drugs with the same name and formula, and helps promote the innovation and development of the Chinese medicine industry.

[0090] Embodiment 2

[0091] In order to better understand the process of this method, an example is used to illustrate the process of the method.

[0092] 1. Construction of databases A, B, and C

[0093] Database A: Basic information database of marketed drugs

[0094] Assume that there is a basic information database A containing a variety of listed Chinese patent medicines. The following is a simplified example data:

[0095]

[0096] The data in this database have been processed and normalized, for example, the drug names have been stripped of dosage forms, and the ATC classification has been classified according to the International Drug Classification Standard.

[0097] Database B: Drug access related database

[0098] Next, build a database B containing drug access related data. The following is a simplified example data:

[0099]

[0100]

[0101] This database contains access-related information such as whether the drug is a protected variety of traditional Chinese medicine, whether it is included in the medical insurance catalogue, whether it belongs to the basic drug catalogue, and whether it is suitable for children.

[0102] Database C: Integrated drug information database

[0103] In database C, a drug entry is created for each drug, and the basic information and access-related data matched from databases A and B are integrated under the corresponding drug entry. The following is a simplified example data:

[0104]

[0105] 2. Screening process of control drugs with the same name and formula

[0106] Assume that the R&D requirement is to find a control drug with the same name and prescription as "Ganmao Qingre Granules". The following is the screening process:

[0107] Determine the filter criteria:

[0108] Drug name: Cold and heat-clearing granules.

[0109] The prescription is the same (since the prescription information is stored in the "prescription" field in database A and has been supplemented through data matching, it can be used as one of the screening conditions).

[0110] Other optional conditions: Based on your needs, you can add filtering conditions such as dosage form, specifications, etc. (for example, non-toxic, manufacturer, etc.). In this example, we mainly focus on the name and prescription, which are just examples.

[0111] Perform a filter:

[0112] Filter out drug entries with the drug name "Ganmao Qingre Granules" from database C.

[0113] Check the prescribing information of these drug entries to ensure that they are identical to the referenced “Ganmao Qingre Granules” prescription.

[0114] If necessary, further screening can be performed based on other screening conditions (such as dosage form, specifications, etc.).

[0115] Result output:

[0116] Assume that after screening, a control drug with the same name and prescription as "Ganmao Qingre Granules" is found, and its drug entry ID is 3 (in actual applications, this ID is automatically generated and used to uniquely identify each drug entry).

[0117] Output detailed information of the control drug, including drug name, English name of the drug, approval number, specifications, prescription, protected Chinese medicine varieties, medical insurance catalog, basic drug catalog, children's medicine, etc.

[0118] Through this process, we can quickly and accurately find control drugs with the same name and formula that meet R&D needs, providing strong support for subsequent R&D work.

[0119] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the technical solution. Those skilled in the art should understand that those modifications or equivalent substitutions of the technical solution of the present invention that do not depart from the purpose and scope of the technical solution should be included in the scope of the claims of the present invention.

Claims

1. A method for screening a control drug of a drug with the same name and formula, characterized in that: The following steps are involved: S1. Obtain basic information of marketed drugs, perform data processing and standardization, and store the processed basic information of drugs in database A; S2. Obtain and process drug access-related data; The processed drug access-related data is stored in database B; S3, using the drug name as a keyword, matching the basic data and access-related data of each drug from database A and database B respectively; Establish drug entries for each drug in database C, and integrate the basic information and access-related data of the matched drugs under the corresponding drug entries; S4. According to the research and development requirements of drugs with the same name and formula, establish screening conditions for control drugs with the same name and formula; and screen the data in database C according to the screening conditions to obtain data of control drugs with the same name and formula that meet the use requirements; Among them, S1 and S2 can be swapped in order.

2. The method for screening a control drug of the same name and formula as claimed in claim 1, characterized in that: In S1, the normalization process includes ATC classification.

3. The method for screening a control drug of the same name and formula as claimed in claim 2, characterized in that: In S1, data processing includes data matching and supplementation and data governance.

4. The method for screening a control drug of the same name and formula as claimed in claim 3, characterized in that: The content of data matching and supplementation includes: using the approval number as the unique value and data matching primary key information; querying the relevant prescription information by matching the corresponding standard source of the instructions, and supplementing the prescription content to the marketed drug data set.

5. The method for screening a control drug of a drug with the same name and formula as claimed in claim 4, characterized in that: The content of data governance includes: removing dosage forms from the names of marketed drugs, and aggregating drugs with the same name to obtain a data set of marketed drug varieties, which is used to standardize drugs with different names but the same prescriptions and to count the number of manufacturers of the same variety.

6. The method for screening a control drug of a drug with the same name and formula as claimed in claim 1, characterized in that: Basic information of drugs, including drug name, English name of the drug, approval number, specifications, number of manufacturers of the same product and number of manufacturers of the same product and specifications, latest and earliest approval dates, ATC classification, dosage form, manufacturer and address, prescription, prescription source, main functions and indications, and registration category.

7. The method for screening a control drug of a drug with the same name and formula as claimed in claim 1, characterized in that: Drug access-related data, including protected Chinese medicine varieties, pharmacopoeia Chinese patent medicine data, medical insurance catalog data, basic drug catalog data, and children's medicine data.

Images